OG
OGEN.US Oragenics Inc
- Market cap
- USD 893K
- P/E
- -
- P/B
- 0.25x
- ROE
- -895.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is OGEN.US undervalued?
Graham numberThe Graham number of Oragenics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Oragenics Inc fundamental analysis
No fundamental analysis for Oragenics Inc yet.
Oragenics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Oragenics Inc
Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical therapies neurological conditions and infectious diseases in the United States. Its lead product is ONP-002, a fully synthetic, non-naturally occurring neurosteroid, which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification for the treatment of…
Full company profileOragenics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Oragenics Inc annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 87.0K | 132K | 37.7K | 0.00 | 0.00 | - |
| Gross Profit | -75.0K | -65.8K | -30.1K | -62.6K | -22.1M | 45.8K | 86.9K | -27.4K | -4.11M | - | - |
| Operating Income | -8.54M | -6.72M | -9.99M | -15.9M | -26.6M | -15.8M | -14.4M | -20.9M | -10.6M | -9.36M | -9.93M |
| EBITDA | -8.42M | -6.45M | -9.88M | -15.5M | -26.6M | -15.7M | -14.2M | -20.6M | -10.5M | -9.19M | -9.89M |
| Net Income | -7.01M | -6.73M | -9.91M | -15.6M | -26.4M | -15.7M | -14.3M | -20.7M | -10.6M | -9.84M | -9.78M |
| EPS | -94 | -82 | -46 | -22 | -28 | -8.35 | -7.11 | -9.18 | -1.60 | -4.56 | -2.17 |
| Balance Sheet | |||||||||||
| Total Assets | 4.31M | 7.21M | 22.0M | 19.8M | 18.7M | 28.2M | 14.8M | 4.97M | 1.47M | 10.1M | 3.28M |
| Total Liabilities | 1.34M | 899K | 1.17M | 2.52M | 1.84M | 1.74M | 1.75M | 1.80M | 1.68M | 1.79M | 2.19M |
| Shareholders' Equity | 2.97M | 6.32M | 20.9M | 17.2M | 16.8M | 26.5M | 13.0M | 3.17M | -212K | 8.28M | 1.09M |
| Cash & Short-term Investments | 4.08M | 6.17M | 20.2M | 18.3M | 17.6M | 27.3M | 11.4M | 3.48M | 865K | 8.40M | 2.23M |
| Total Debt | 66.4K | 80.5K | 124K | 980K | 899K | 797K | 625K | 323K | 329K | 227K | 397K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -7.08M | -6.36M | -9.08M | -13.0M | -17.0M | -13.5M | -15.2M | -7.29M | -8.60M | -9.25M | -8.56M |
| Capital Expenditure | 27.2K | 125K | 125K | 25.2K | 43.9K | 43.9K | 128K | 1.00M | 0.00 | 3.00 | 10.67 |
| Free Cash Flow | -7.10M | -6.36M | -9.20M | -13.0M | -17.0M | -13.5M | -15.4M | -8.29M | -8.60M | -9.25M | -8.56M |
| Ratios | |||||||||||
| ROE | -236.5% | -106.6% | -47.5% | -90.4% | -156.9% | -59.3% | -109.8% | -652.0% | - | -118.9% | -895.0% |
| ROA | -162.8% | -93.3% | -45.0% | -78.8% | -141.5% | -55.7% | -96.8% | -415.9% | -717.7% | -97.8% | -297.9% |
| Net Profit Margin | - | - | - | - | - | -18,062.0% | -10,864.0% | -54,858.1% | - | - | - |
| Debt to Equity | 0.02x | 0.01x | 0.01x | 0.06x | 0.05x | 0.03x | 0.05x | 0.10x | - | 0.03x | 0.36x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Oragenics Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | USD 1.12M | 0.56 | - |
| 2021 | USD 1.12M | 0.59 | - |
| 2020 | USD 661K | 0.70 | - |
| 2019 | USD 413K | 0.59 | - |
| 2018 | USD 58.7K | 0.27 | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:30 on Jun 3, 2025.
Who owns Oragenics Inc
- Insiders 1.93%
- Institutions 3.69%
- Public & others 94.38%
- Shares outstanding 4.51M
- Free float 4.42M
Oragenics Inc company profile
- Company name
- Oragenics Inc
- Ticker
- OGEN.US
- Exchange
- USA Stocks
- Listed since
- Feb 25, 2004
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 3
- Fiscal year end
- December
- Address
- 9015 Town Center Parkway, Lakewood Ranch, FL, United States, 34202
- Phone
- 813 286 7900
- Website
- oragenics.com
About Oragenics Inc
Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical therapies neurological conditions and infectious diseases in the United States. Its lead product is ONP-002, a fully synthetic, non-naturally occurring neurosteroid, which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification for the treatment of mild traumatic brain injury. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Lakewood Ranch, Florida.
Oragenics Inc management
4- Ms. Janet HuffmanCEO, President, Secretary & Treasurer · born 1972
- Mr. John SpencerChief Financial Officer · born 1994
- Dr. James P. Kelly M.A., M.D.Chief Medical Officer
- Dr. William Franklin Peacock IV, F.A.C.E.P., FACC, M.D.Chief Clinical Officer